Clinical Trials on Primary Myelofibrosis in Netherlands

Total 1656 results

Stichting Hemato-Oncologie voor Volwassenen Nederland
CTI BioPharma; Dutch Cancer Society

Active, not recruiting

Myelofibrosis Treated With Pacritinib Before aSCT. (HOVON134MF) (HOVON134MF)

Myelofibrosis

Netherlands, Belgium
Novartis Pharmaceuticals

Completed

Study of the Safety of PIM447 in Combination With Ruxolitinib (INC424) and LEE011 in Patients With Myelofibrosis

Myelofibrosis

United Kingdom, Germany, Canada, Singapore, Netherlands, Italy, Australia, France
Incyte Corporation
Novartis

Completed

Study of the JAK Inhibitor Ruxolitinib Administered Orally to Patients With Primary Myelofibrosis (PMF), Post-Polycythemia Vera-Myelofibrosis (PPV-MF) or Post-Essential Thrombocythemia-Myelofibrosis (PET-MF)

Myelofibrosis

France, United Kingdom, China, United States, Netherlands, Germany, Italy, Austria
Novartis Pharmaceuticals

Active, not recruiting

Platform Study of Novel Ruxolitinib Combinations in Myelofibrosis Patients (ADORE)

Myelofibrosis

United Kingdom, Australia, Canada, Switzerland, Netherlands, Spain, Germany, Italy, Turkey, Russian Federation, Sweden, Denmark, Hungary
AbbVie

Active, not recruiting

Study of Oral Navitoclax Tablet In Combination With Oral Ruxolitinib Tablet When Compared With Oral Ruxolitinib Tablet To Assess Change In Spleen Volume In Adult Participants With Myelofibrosis (TRANSFORM-1)

Myelofibrosis (MF)

United States, Australia, Austria, Belgium, Bulgaria, Canada, Croatia, France, Germany, Greece, Israel, Italy, Japan, Korea, Republic of, Netherlands, New Zealand, Russian Federation, Serbia, South Africa, Spain, Sweden, Taiwan, Turkey and more
Celgene

Completed

Study of Pomalidomide in Persons With Myeloproliferative-Neoplasm-Associated Myelofibrosis and RBC-Transfusion-Dependence (RESUME)

Primary Myelofibrosis | MPN-associated Myelofibrosis

United States, Netherlands, France, Australia, Italy, United Kingdom, Canada, Germany, China, Spain, Belgium, Austria, Poland, Sweden, Japan, Russian Federation
Incyte Corporation

Completed

A Study of Itacitinib in Combination With Low-Dose Ruxolitinib or Itacitinib Alone Following Ruxolitinib in Participants With Myelofibrosis

MPN (Myeloproliferative Neoplasms)

United States, Netherlands, Austria
Sanofi

Completed

Phase II, Open Label, Single Arm Study of SAR302503 In Myelofibrosis Patients Previously Treated With Ruxolitinib (JAKARTA2)

Hematopoietic Neoplasm

United States, Austria, Belgium, Canada, France, Germany, Italy, Netherlands, Spain, United Kingdom
GlaxoSmithKline

Active, not recruiting

Extended Access of Momelotinib in Adults With Myelofibrosis

Neoplasms | Primary Myelofibrosis (PMF) | Post-polycythemia Vera Myelofibrosis (Post-PV MF) | Post-essential Thrombocythemia Myelofibrosis (Post-ET MF)

United States, Hungary, Israel, Spain, Taiwan, France, Australia, Germany, Belgium, Canada, Singapore, Korea, Republic of, United Kingdom, Denmark, Austria, Romania, Italy, Bulgaria, Poland, Netherlands
Novartis Pharmaceuticals

Completed

Controlled Myelofibrosis Study With Oral Janus-associated Kinase (JAK) Inhibitor Treatment-II: The COMFORT-II Trial

Myelofibrosis

France, United Kingdom, Belgium, Germany, Netherlands, Italy, Austria, Spain, Sweden
Hoffmann-La Roche

Completed

A Phase 2 Study of RO7490677 In Participants With Myelofibrosis

Primary Myelofibrosis | Polycythemia Vera | Post-Essential Thrombocythemia Myelofibrosis

United States, Netherlands, Italy, United Kingdom, Canada, France, Germany, Israel
Sierra Oncology, Inc.

Completed

Momelotinib Versus Ruxolitinib in Subjects With Myelofibrosis (Simplify 1)

Primary Myelofibrosis | Post-Polycythemia Vera Myelofibrosis | Post-Essential Thrombocythemia Myelofibrosis

United States, France, Germany, Spain, Israel, Bulgaria, Romania, Japan, Taiwan, Korea, Republic of, Australia, Belgium, Canada, Netherlands, Singapore, Poland, Hungary, Denmark, Sweden, United Kingdom, Czechia, Austria
Constellation Pharmaceuticals

Active, not recruiting

Phase 3 Study of Pelabresib (CPI-0610) in Myelofibrosis (MF) (MANIFEST-2) (MANIFEST-2)

Primary Myelofibrosis | Myelofibrosis | Post-polycythemia Vera Myelofibrosis | Post-essential Thrombocythemia Myelofibrosis

Korea, Republic of, Spain, United States, Canada, Taiwan, Czechia, United Kingdom, Australia, Italy, Belgium, Germany, France, Israel, Greece, Malaysia, Netherlands, Austria, Turkey, Poland, Thailand, Hong Kong, Hungary
CTI BioPharma

Terminated

Pacritinib Versus Best Available Therapy to Treat Myelofibrosis

Primary Myelofibrosis | Post-polycythemia Vera Myelofibrosis | Post-essential Thrombocythemia Myelofibrosis

United States, Australia, Belgium, Czechia, France, Germany, Hungary, Italy, Netherlands, New Zealand, Russian Federation, United Kingdom
CTI BioPharma

Terminated

Pacritinib Versus Best Available Therapy to Treat Patients With Myelofibrosis and Thrombocytopenia (PAC326)

Primary Myelofibrosis | Post-polycythemia Vera Myelofibrosis | Post-essential Thrombocythemia Myelofibrosis

United States, Canada, France, United Kingdom, Australia, Belgium, Germany, New Zealand, Netherlands, Russian Federation, Hungary, Czechia
Celgene

Recruiting

A Study to Evaluate Long-term Safety in Participants Who Have Participated in Other Luspatercept (ACE-536) Clinical Trials

Beta-thalassemia | Myelodysplastic Syndromes (MDS) | Myeloproliferative Neoplasm(MPN)-Associated Myelofibrosis

United States, Japan, Israel, United Kingdom, Turkey, Greece, France, Australia, Belgium, Bulgaria, Canada, Germany, Italy, Malaysia, Spain, Sweden, Taiwan, Thailand, Tunisia, China, Lebanon, Netherlands
Celgene
Impact Biomedicines, Inc., a wholly owned subsidiary of Celgene Corporation

Active, not recruiting

An Efficacy and Safety Study of Fedratinib Compared to Best Available Therapy in Subjects With DIPSS-intermediate or High-risk Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, or Post-essential Thrombocythemia Myelofibrosis and Previously Treated With Ruxolitinib (FREEDOM2)

Primary Myelofibrosis | Myelofibrosis | Post-Polycythemia Vera

Australia, Austria, Belgium, China, Czechia, France, Germany, Hungary, Italy, Korea, Republic of, Netherlands, Poland, Russian Federation, Spain, Ireland, United Kingdom
Dicerna Pharmaceuticals, Inc.

Terminated

A Study of DCR-PH1 in Patients With Primary Hyperoxaluria Type 1 (PH1)

Primary Hyperoxaluria Type 1

Netherlands, Germany
Constellation Pharmaceuticals
The Leukemia and Lymphoma Society

Active, not recruiting

A Phase 2 Study of CPI-0610 With and Without Ruxolitinib in Patients With Myelofibrosis

Neoplasms | Neoplasms by Histologic Type | Leukemia | Preleukemia | Primary Myelofibrosis | Myeloproliferative Disorders | Myelofibrosis | Precancerous Conditions | Myelodysplastic/Myeloproliferative Neoplasm | Myelodysplastic Syndrome (MDS) | Leukemia, Myelocytic, Acute | Bone Marrow Disease | Hematological Disease and other conditions

Canada, United States, United Kingdom, Germany, Italy, Belgium, France, Netherlands, Poland
Novartis Pharmaceuticals

Completed

A Phase Ib/II Dose-finding Study to Assess the Safety and Efficacy of LDE225 + INC424 in Patients With MF

Bone Marrow Diseases | Hematologic Diseases | Blood Coagulation Disorders | Hemorrhagic Disorders | Primary Myelofibrosis | Myeloproliferative Disorders | Polycythemia Vera | Thrombocytosis | Essential Thrombocythemia | Blood Platelet Disorders

United Kingdom, Belgium, Canada, France, Australia, Netherlands, Spain, Denmark, Ireland, Italy, Germany
UMC Utrecht
Erasmus Medical Center; Amsterdam UMC, location VUmc

Completed

Primary Ovarian Insufficiency, Polycystic Ovary Syndrome & the CardiOvascular Risk Profile (POPCORn)

Cardiovascular Diseases

Netherlands
Medigene AG

Withdrawn

HA-1H TCR T Cell for Relapsed/Persistent Hematologic Malignancies After Allogeneic Stem Cell Transplantation

Acute Myeloid Leukemia | Myelodysplastic Syndromes | Myeloproliferative Disorders | Multiple Myeloma | Myelofibrosis | Chronic Myeloid Leukemia | Acute Lymphoid Leukemia | Malignant Lymphoma

Netherlands
Maastricht University

Active, not recruiting

Healthy Childcare Centre of the Future (HCCF)

Health and Wellbeing of Primary School-aged Children

Netherlands
Maastricht University Medical Center
ZonMw: The Netherlands Organisation for Health Research and Development

Active, not recruiting

SIGHT Study: Cost-effectiveness of InnFocus Microshunt Implantation vs. Trabeculectomy. (SIGHT)

Primary Open-angle Glaucoma

Netherlands
Radboud University Medical Center

Completed

Primary Aldosteronism in General Practice: Organ Damage, Epidemiology and Treatment (PAGODE)

Primary Aldosteronism | Primary Hyperaldosteronism

Netherlands
Novartis Pharmaceuticals

Completed

Expanded Access of Deferasirox to Patients With Congenital Disorders of Red Blood Cells and Chronic Iron Overload

Myelofibrosis | Sickle Cell Disease | Thalassemia | Diamond Blackfan Anemia

United States, Netherlands, Taiwan, Thailand, Italy, Germany, Spain, Canada, Belgium, Greece, Turkey, United Kingdom
University Medical Center Groningen

Enrolling by invitation

Effects of Communication Training to Involve Older People in Decisions to DEPRESCRIBE Cardiometabolic Medication: a Cluster-randomized Trial in Primary Care (CO-DEPRESCRIBE)

Primary Health Care | Polypharmacy | Deprescriptions | Community Pharmacy Services | Decision Making, Shared

Netherlands
Radboud University Medical Center
Terumo Medical Corporation

Completed

Clinical Validation of a Fractional Administration Device for Holmium-166 SIRT (CONTROL)

Primary Liver Cancer | Liver Cancer | Liver Metastasis Colon Cancer

Netherlands
OxThera

Completed

Phase 2/3 Oxabact Study

Primary Hyperoxaluria

United States, Germany, Netherlands
The Netherlands Cancer Institute

Recruiting

The Prospective Observational COMPRAYA Cohort Study (COMPRAYA)

Cancer | Fertility Issues | Genetic Disease | Lifestyle | Survivorship | Distress, Emotional | Second Cancer

Netherlands
UMC Utrecht

Completed

Early Detection of Primary Antibody Deficiencies in Primary Care Facilities by an Algorithm Driven Selection of Serologic Testing in Individuals at Risk. (GP-PAD II)

Primary Antibody Deficiencies

Netherlands
Academisch Ziekenhuis Maastricht

Unknown

Chemotherapy in Treating Patients With Cancer of Unknown Primary Origin

Carcinoma of Unknown Primary

Netherlands
University Medical Center Groningen

Recruiting

Investigating Cardiovascular Adverse Events Related to Cancer Treatment (InvestiCAT)

Toxicity Due to Chemotherapy | Cancer, Treatment-Related | Cardiovascular Morbidity

Netherlands
UMC Utrecht
University Medical Center Groningen; Erasmus Medical Center; Catharina Ziekenhuis... and other collaborators

Unknown

Pheno- & Genotyping POF (WHO III)

Premature Ovarian Failure (POF) | Incipient Ovarian Failure | Poor Response After Ovarian Hyperstimulation | Early Menopause | Hypergonadotropic Amenorrhea

Netherlands
SIR Institute for Pharmacy Practice and Policy

Recruiting

Optimising Medication With Focus on Deprescribing in Frail Older People With Multidose Drug Dispensing Systems

Primary Health Care | Polypharmacy | Deprescriptions | Community Pharmacy Services

Netherlands
Radboud University Medical Center

Completed

Nijmegen Antihypertensive Management Improvement Study (NAMIS)

Primary Hypertension

Netherlands
Maastricht University Medical Center

Completed

Basic Sensations Coming From the Bladder

Healthy | Overactive Bladder Syndrome

Netherlands
Radboud University Medical Center
Terumo Medical Corporation

Enrolling by invitation

MRI-guided Holmium-166 Radioembolization (EMERITUS-2)

Primary Liver Cancer | Non-Resectable Hepatocellular Carcinoma

Netherlands
Astellas Pharma Europe Ltd.

Terminated

An Exploratory Study to Investigate Bladder Contractions in the Storage Phase and Related Bladder Sensations in Healthy Females and Females With Overactive Bladder (OAB) Using High Resolution and Conventional Urodynamics

Overactive Bladder | Healthy Subjects

Netherlands
Radboud University Medical Center
Astellas Pharma Inc; Continentie Stichting Nederland (Continence Foundation...

Unknown

Study of Overactive Bladder in Women With Prolapse (SOAP)

Urinary Bladder, Overactive | Pelvic Organ Prolapse

Netherlands
Taris Biomedical LLC

Completed

Safety and Tolerability of TAR-200 mg in Subjects With Non-Muscle-Invasive Bladder Cancer

Urinary Bladder Cancer

Netherlands
Maastricht University Medical Center

Unknown

Non-Micturation Bladder Activity in Relation to Self-Consciousness During Filling Phase and Sensation Measurement During the Filling Phase

Lower Urinary Tract Symptoms | Overactive Bladder Syndrome

Netherlands
Clinical Research Office of the Endourological...

Active, not recruiting

Registry for Treatment of Upper Urinary Tract Tumours

Upper Urinary Tract Tumours

Netherlands
Maastricht University Medical Center
University Hospital, Antwerp; Zuyderland Hospital

Unknown

Experience Sampling Method in OAB Patients

Overactive Bladder | Overactive Bladder Syndrome

Netherlands
University Medical Center Groningen

Recruiting

Real-time Targeted Fluorescence Endoscopy for Detection of the Primary Cancer Lesion in Patients With a Metastasis of Unknown Primary Tumor in the Head and Neck (REFLECT)

Oropharynx Cancer | Unknown Primary Tumors

Netherlands
Radboud University Medical Center

Completed

Urgent-SQ in Treatment of Overactive Bladder Syndrome: 9-yr Follow up

Overactive Bladder | Urinary Incontinence, Urge | Urinary Frequency or Urgency Adverse Event

Netherlands
Neuspera Medical, Inc.

Completed

Acute Study to Evaluate a Novel Implantable Midfield Powered Device in Humans With Urinary Incontinence

Overactive Bladder

Netherlands
Maastricht University Medical Center

Completed

Time of Effect Onset in Treating Overactive Bladder or Non Obstructive Urinary Retention by Sacral Neuromodulation

Overactive Bladder | Non Obstructive Urinary Retention

Netherlands
Radboud University Medical Center
Stichting Kwaliteit en Ontwikkeling Huisartsenzorg; GP Cooperative Emmen (CHD...

Completed

The (Cost-)Effectiveness of Physician Assistants Working at the Primary Out of Hours Emergency Service

Primary Healthcare | Out-of-hours Medical Care

Netherlands
Maastricht University Medical Center
Scientific Foundation Urology Maastricht

Completed

Screening Method in Sacral Neuromodulation

Overactive Bladder | Urinary Retention

Netherlands

Clinical Trials on Primary Myelofibrosis in Netherlands

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Togo

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations